JAK2 and essential thrombocythemia: The ET patients with CALR mutations had a significantly lower white blood cell count (p < 0.001), NAP score (p < 0.001), and prevalence of thrombotic events than the patients with JAK2 mutations (p = 0.023; Table 1).